The value of routine blood work-up in clinical stratification and prognosis of patients with amyotrophic lateral sclerosis.
Amyotrophic lateral sclerosis
Biomarkers
Blood
Survival
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
19
07
2023
accepted:
19
09
2023
revised:
18
09
2023
medline:
6
10
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
aheadofprint
Résumé
There is an unmet need in amyotrophic lateral sclerosis (ALS) to provide specific biomarkers for the disease. Due to their easy availability, we aimed to investigate whether routine blood parameters provide useful clues for phenotypic classification and disease prognosis. We analyzed a large inpatient cohort of 836 ALS patients who underwent deep phenotyping with evaluation of the clinical and neurophysiological burden of upper (UMN) and lower (LMN) motor neuron signs. Disability and progression rate were measured through the revised ALS Functional Rating Scale (ALSFRS-R) and its changes during time. Cox regression analysis was performed to assess survival associations. Creatinine significantly correlated with LMN damage (r = 0.38), active (r = 0.18) and chronic (r = 0.24) denervation and baseline ALSFRS-R (r = 0.33). Creatine kinase (CK), alanine (ALT) and aspartate (AST) transaminases correlated with active (r = 0.35, r = 0.27, r = 0.24) and chronic (r = 0.37, r = 0.20, r = 0.19) denervation, while albumin and C-reactive protein significantly correlated with LMN score (r = 0.20 and r = 0.17). Disease progression rate showed correlations with chloride (r = -0.19) and potassium levels (r = -0.16). After adjustment for known prognostic factors, total protein [HR 0.70 (95% CI 0.57-0.86)], creatinine [HR 0.86 (95% CI 0.81-0.92)], chloride [HR 0.95 (95% CI 0.92-0.99)], lactate dehydrogenase [HR 0.99 (95% CI 0.99-0.99)], and AST [HR 1.02 (95% CI 1.01-1.02)] were independently associated with survival. Creatinine is a reliable biomarker for ALS, associated with clinical features, disability and survival. Markers of nutrition/inflammation may offer additional prognostic information and partially correlate with clinical features. AST and chloride could further assist in predicting progression rate and survival.
Sections du résumé
BACKGROUND
BACKGROUND
There is an unmet need in amyotrophic lateral sclerosis (ALS) to provide specific biomarkers for the disease. Due to their easy availability, we aimed to investigate whether routine blood parameters provide useful clues for phenotypic classification and disease prognosis.
METHODS
METHODS
We analyzed a large inpatient cohort of 836 ALS patients who underwent deep phenotyping with evaluation of the clinical and neurophysiological burden of upper (UMN) and lower (LMN) motor neuron signs. Disability and progression rate were measured through the revised ALS Functional Rating Scale (ALSFRS-R) and its changes during time. Cox regression analysis was performed to assess survival associations.
RESULTS
RESULTS
Creatinine significantly correlated with LMN damage (r = 0.38), active (r = 0.18) and chronic (r = 0.24) denervation and baseline ALSFRS-R (r = 0.33). Creatine kinase (CK), alanine (ALT) and aspartate (AST) transaminases correlated with active (r = 0.35, r = 0.27, r = 0.24) and chronic (r = 0.37, r = 0.20, r = 0.19) denervation, while albumin and C-reactive protein significantly correlated with LMN score (r = 0.20 and r = 0.17). Disease progression rate showed correlations with chloride (r = -0.19) and potassium levels (r = -0.16). After adjustment for known prognostic factors, total protein [HR 0.70 (95% CI 0.57-0.86)], creatinine [HR 0.86 (95% CI 0.81-0.92)], chloride [HR 0.95 (95% CI 0.92-0.99)], lactate dehydrogenase [HR 0.99 (95% CI 0.99-0.99)], and AST [HR 1.02 (95% CI 1.01-1.02)] were independently associated with survival.
CONCLUSIONS
CONCLUSIONS
Creatinine is a reliable biomarker for ALS, associated with clinical features, disability and survival. Markers of nutrition/inflammation may offer additional prognostic information and partially correlate with clinical features. AST and chloride could further assist in predicting progression rate and survival.
Identifiants
pubmed: 37801095
doi: 10.1007/s00415-023-12015-3
pii: 10.1007/s00415-023-12015-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Feldman EL et al (2022) Amyotrophic lateral sclerosis. Lancet 400(10360):1363–1380
pubmed: 36116464
doi: 10.1016/S0140-6736(22)01272-7
Verde F, Otto M, Silani V (2021) Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 15:679199
pubmed: 34234641
pmcid: 8255624
doi: 10.3389/fnins.2021.679199
Verde F et al (2019) Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90(2):157–164
pubmed: 30309882
doi: 10.1136/jnnp-2018-318704
Hertel N et al (2022) Analysis of routine blood parameters in patients with amyotrophic lateral sclerosis and evaluation of a possible correlation with disease progression-a multicenter study. Front Neurol 13:940375
pubmed: 35968316
pmcid: 9364810
doi: 10.3389/fneur.2022.940375
van Eijk RPA et al (2018) Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry 89(2):156–161
pubmed: 29084868
doi: 10.1136/jnnp-2017-317077
Chio A et al (2014) Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol 71(9):1134–1142
pubmed: 25048026
doi: 10.1001/jamaneurol.2014.1129
Lunetta C et al (2017) Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol 74(6):660–667
pubmed: 28384752
pmcid: 5822215
doi: 10.1001/jamaneurol.2016.6179
Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299
pubmed: 11464847
doi: 10.1080/146608200300079536
Woo JH et al (2014) Linear associations between clinically assessed upper motor neuron disease and diffusion tensor imaging metrics in amyotrophic lateral sclerosis. PLoS ONE 9(8):e105753
pubmed: 25144708
pmcid: 4140827
doi: 10.1371/journal.pone.0105753
Devine MS et al (2016) Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 17(3–4):184–190
pubmed: 26700804
doi: 10.3109/21678421.2015.1125502
Maranzano A et al (2022) Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. Eur J Neurol 29(5):1402–1409
pubmed: 34989063
doi: 10.1111/ene.15243
Colombo E et al (2022) Correlation between clinical phenotype and electromyographic parameters in amyotrophic lateral sclerosis. J Neurol 270:511–518
pubmed: 36183286
pmcid: 9813173
doi: 10.1007/s00415-022-11404-4
Cedarbaum JM et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1–2):13–21
pubmed: 10540002
doi: 10.1016/S0022-510X(99)00210-5
Ratti A et al (2022) Genetic and epigenetic disease modifiers in an Italian C9orf72 family expressing ALS, FTD or PD clinical phenotypes. Amyotroph Lateral Scler Frontotemporal Degener 23(3–4):292–298
pubmed: 34382491
doi: 10.1080/21678421.2021.1962355
Palmqvist S et al (2021) Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27(6):1034–1042
pubmed: 34031605
doi: 10.1038/s41591-021-01348-z
Burnham KP, Anderson DR (2016) Multimodel Inference. Sociol Methods Res 33(2):261–304
doi: 10.1177/0049124104268644
Slinker BK, Glantz SA (1985) Multiple regression for physiological data analysis: the problem of multicollinearity. Am J Physiol 249(1 Pt 2):R1–R12
pubmed: 4014489
Cui C et al (2020) Creatinine and C-reactive protein in amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease. Brain Commun 2(2):fcaa152
pubmed: 33543134
pmcid: 7850290
doi: 10.1093/braincomms/fcaa152
Kuffner R et al (2015) Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol 33(1):51–57
pubmed: 25362243
doi: 10.1038/nbt.3051
Holdom CJ et al (2021) Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis. Eur J Neurol 28(11):3615–3625
pubmed: 34216521
doi: 10.1111/ene.15003
Tetsuka S et al (2013) Utility of cystatin C for renal function in amyotrophic lateral sclerosis. Acta Neurol Scand 128(6):386–390
pubmed: 23802939
doi: 10.1111/ane.12134
Sun J et al (2020) Blood biomarkers and prognosis of amyotrophic lateral sclerosis. Eur J Neurol 27(11):2125–2133
pubmed: 32557963
doi: 10.1111/ene.14409
Chen X et al (2019) Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 20(1–2):53–60
pubmed: 30784318
doi: 10.1080/21678421.2018.1550516
Mandrioli J et al (2019) Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS). BMJ Open 9(5):e028486
pubmed: 31152038
pmcid: 6549675
doi: 10.1136/bmjopen-2018-028486
Warnes TW et al (1987) A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 5(1):1–7
pubmed: 3655305
doi: 10.1016/S0168-8278(87)80053-3
Mirian A, Korngut L (2018) The utility of the laboratory work up at the time of diagnosis of amyotrophic lateral sclerosis. J Neuromuscul Dis 5(1):35–38
pubmed: 29278899
doi: 10.3233/JND-170281
Bond L et al (2020) Associations of patient mood, modulators of quality of life, and pharmaceuticals with amyotrophic lateral sclerosis survival duration. Behav Sci (Basel) 10(1):33
pubmed: 31936812
doi: 10.3390/bs10010033
Beers DR et al (2020) Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis. Sci Rep 10(1):15295
pubmed: 32943739
pmcid: 7499429
doi: 10.1038/s41598-020-72247-5
Kharel S et al (2022) C-reactive protein levels in patients with amyotrophic lateral sclerosis: a systematic review. Brain Behav 12(3):e2532
pubmed: 35201675
pmcid: 8933772
doi: 10.1002/brb3.2532
Nagel G et al (2017) Adipokines, C-reactive protein and amyotrophic lateral sclerosis—results from a population-based ALS registry in Germany. Sci Rep 7(1):4374
pubmed: 28663573
pmcid: 5491500
doi: 10.1038/s41598-017-04706-5
De Schaepdryver M et al (2020) Neurofilament light chain and C reactive protein explored as predictors of survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 91(4):436–437
pubmed: 32029541
doi: 10.1136/jnnp-2019-322309
Lunetta C et al (2015) Amyotrophic lateral sclerosis survival score (ALS-SS): a simple scoring system for early prediction of patient survival. Amyotroph Lateral Scler Frontotemporal Degener 17(1–2):93–100
pubmed: 26470943
Qureshi M et al (2008) Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9(6):369–374
pubmed: 18608098
doi: 10.1080/17482960802163614
Nakano Y, Hirayama K, Terao K (1987) Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch Neurol 44(1):103–106
pubmed: 3800708
doi: 10.1001/archneur.1987.00520130079022
Lee SH, Yang EJ (2018) Relationship between liver pathology and disease progression in a murine model of amyotrophic lateral sclerosis. Neurodegener Dis 18(4):200–207
pubmed: 30130789
doi: 10.1159/000491392
Manera U et al (2023) Serum chloride as a respiratory failure marker in amyotrophic lateral sclerosis. Front Aging Neurosci 15:1188827
pubmed: 37293667
pmcid: 10244551
doi: 10.3389/fnagi.2023.1188827
Gao J et al (2022) Creatine kinase and prognosis in amyotrophic lateral sclerosis: a literature review and multi-centre cohort analysis. J Neurol 269(10):5395–5404
pubmed: 35614165
pmcid: 9467954
doi: 10.1007/s00415-022-11195-8
Rafiq MK et al (2016) Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis. Eur J Neurol 23(6):1071–1078
pubmed: 27029589
doi: 10.1111/ene.12995
Ito D et al (2019) Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol 266(12):2952–2961
pubmed: 31456060
doi: 10.1007/s00415-019-09507-6
Chen XP et al (2021) Creatine kinase in the diagnosis and prognostic prediction of amyotrophic lateral sclerosis: a retrospective case-control study. Neural Regen Res 16(3):591–595
pubmed: 32985493
doi: 10.4103/1673-5374.293159
Tai H et al (2017) Correlation of creatine kinase levels with clinical features and survival in amyotrophic lateral sclerosis. Front Neurol 8:322
pubmed: 28717355
pmcid: 5494475
doi: 10.3389/fneur.2017.00322
Tai H et al (2018) Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis. Clin Neurophysiol 129(5):926–930
pubmed: 29550653
doi: 10.1016/j.clinph.2018.01.071
Colombo E et al (2022) Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis. J Neurol 270(2):898–908
pubmed: 36308529
pmcid: 9886586
doi: 10.1007/s00415-022-11433-z
Ingre C et al (2020) Lipids, apolipoproteins, and prognosis of amyotrophic lateral sclerosis. Neurology 94(17):e1835–e1844
pubmed: 32221024
pmcid: 7274849
doi: 10.1212/WNL.0000000000009322
Paganoni S et al (2018) Urate levels predict survival in amyotrophic lateral sclerosis: analysis of the expanded pooled resource open-access ALS clinical trials database. Muscle Nerve 57(3):430–434
pubmed: 28857199
doi: 10.1002/mus.25950
Thompson AG et al (2022) Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun 4(1):fcac029
pubmed: 35224491
pmcid: 8870425
doi: 10.1093/braincomms/fcac029
Yazdani S et al (2019) Peripheral immune biomarkers and neurodegenerative diseases: a prospective cohort study with 20 years of follow-up. Ann Neurol 86(6):913–926
pubmed: 31604369
pmcid: 7611591
doi: 10.1002/ana.25614
Tang J et al (2021) Plasma uric acid helps predict cognitive impairment in patients with amyotrophic lateral sclerosis. Front Neurol 12:789840
pubmed: 34938266
pmcid: 8685604
doi: 10.3389/fneur.2021.789840
Chio A et al (2011) Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 82(7):740–746
pubmed: 21402743
doi: 10.1136/jnnp.2010.235952
Falzone YM et al (2022) Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol 29(7):1930–1939
pubmed: 35263489
pmcid: 9314044
doi: 10.1111/ene.15321